共 112 条
[1]
Coresh J(2007)Prevalence of chronic kidney disease in the United States JAMA. 298 2038-2047
[2]
Selvin E(2013)Age-Related changes in the prevalence of osteoporosis according to gender and skeletal site: the Korea National Health and Nutrition Examination Survey 2008-2010 Endocrinol Metab (Seoul). 28 180-191
[3]
Stevens LA(2007)Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial J Bone Miner Res. 22 503-508
[4]
Manzi J(2005)Treatment of osteoporosis in chronic kidney disease and end-stage renal disease Curr Osteoporos Rep. 3 5-12
[5]
Kusek JW(1999)Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial JAMA. 282 1344-1352
[6]
Eggers P(2000)Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporos Int. 11 83-91
[7]
van Lente F(2005)Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials Bone Miner Res. 20 2105-2115
[8]
Levey AS(1975)Renal secretion of diphosphonates in rats Kidney Int. 8 6-13
[9]
Lee J(2009)Bisphosphonate nephrotoxicity Kidney Int. 74 1385-1393
[10]
Lee S(2013)Renal safety in patients treated with bisphosphonates for osteoporosis: a review J Bone Miner Res. 28 2049-2059